Trial Profile

Proof-of-concept phase II trial of R 118 in patients with intermittent claudication

Status: Withdrawn prior to enrolment

Phase of Trial: Phase II

Latest Information Update: 13 Oct 2014

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs R 118 (Primary)
Indications Intermittent claudication
Focus Proof of concept; Therapeutic Use

Most Recent Events

13 Aug 2014 Rigel Pharmaceuticals has discontinued the R 118 programme due to the side-effect profile in phase I trials, according to a media release.
13 Aug 2014 Status changed from planning to withdrawn prior to enrolment, according to a Rigel Pharmaceuticals media release.
13 Mar 2014 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com